Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 217,41 pts
+0.01%


Last updated : 18/11/2026 - 09h06
🏠 Home   ➤    Stock news

Innate Pharma: 33% response for IPH4502 at maximum dose in phase 1

Innate Pharma presented first phase 1 data for IPH4502, its antibody-drug conjugate targeting Nectin-4 and carrying an exatecan payload, at the EORTC-NCI-AACR symposium (ENA 2026) on 18 November 2026.

Antitumor activity was observed in several tumor types. In patients with urothelial cancer, this activity was measured at intermediate doses, none of them having received the maximum tolerated dose.


Innate Pharma: 33% response for IPH4502 at maximum dose in phase 1

Activity observed in six patients at the maximum tolerated dose

The dose-escalation study included 76 patients with advanced solid tumors, treated at six dose levels between 0.6 and 3.6 mg/kg every three weeks. These patients had received a median of 3.5 prior lines of treatment and presented more than 10 tumor types. The primary objective of the study was tolerability.

At the maximum tolerated dose of 3.6 mg/kg, the objective response rate reached 33% in non-urothelial tumors, i.e., 2 patients out of 6. According to the company, responses were observed regardless of Nectin-4 expression level, whether low, moderate or high.

All 19 patients with urothelial cancer had previously received enfortumab vedotin. Fifteen were treated at 2.4 or 2.8 mg/kg and four at 3.2 mg/kg. Three partial responses were recorded, including one confirmed and two unconfirmed.

Tumor reduction was observed in the majority of these patients. The unconfirmed disease control rate stands at 68.4%, with a 95% confidence interval between 46.0% and 84.6%.

Grade 3 or higher adverse events in 43.4% of patients

As of the data cutoff date of 17 August 2026, the company described a well-tolerated product, with overall low hematologic toxicity. Stomatitis is the only dose-limiting toxicity reported. No febrile neutropenia or signal of peripheral neuropathy was observed.

Grade 3 or higher adverse events nevertheless occurred in 43.4% of patients, including grade 3 or higher anemia in 11.8%. Stomatitis affected 27.6% of patients, with 3.9% of grade 3 or higher cases.

These events led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%. The dose optimization phase, whose first patient is expected in the first half of 2027, will focus on urothelial cancer treated after enfortumab vedotin, in second line or beyond.

It will test fractionated administration on days 1 and 8 of each three-week cycle, with mandatory prophylaxis aimed at reducing stomatitis. "Our priority is now to optimize the dose and the administration schedule," said Jonathan Dickinson, chief executive officer, in order to guide the selection of a recommended phase 2 dose.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,4 millions d'euros
  • Quarterly revenue: 3,4 millions d'euros
  • Revenue growth: 47,8 %
Risks mentioned
  • Horizon de trésorerie limité à fin Q1 2028 indiquant une dépendance aux résultats d'essais cliniques futurs
  • Résultats de PACIFIC-9 reprogrammés du S2 2026 au S1 2027, retard lié à la nature de l'essai événement-dépendant
  • Programme de développement concentré sur des actifs en phase clinique sans revenue significative
Opportunities identified
  • Présentation des données de Phase 1 d'IPH4502 (ADC anti-Nectine-4) au congrès ENA le 18 novembre 2026
  • Traitement du premier patient dans l'étude de Phase 3 TELLOMAK-3 (lacutamab) prévu au premier trimestre 2027
  • Dépôt de demande d'autorisation accélérée FDA pour lacutamab prévu au second semestre 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours